Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults
- Author
- Isabel Leroux-Roels (UGent) , Eva Vets, Ralf Freese, Michael Seiberling, Francoise Weber, Camille Salamand and Geert Leroux-Roels (UGent)
- Organization
- Abstract
- Influenza vaccines remain largely underused. A promising alternative to Current intramuscular vaccines is a trivalent inactivated influenza vaccine (TIV) delivered using a microinjection system to offer a less invasive and possibly more acceptable vaccination. A phase 11, multicentre, randomised open-label study in 978 healthy adults (18-57 years) evaluated the immunogenicity and safety of intradermal TIV. Subjects received a 0.1 ml injection of intradermal TIV, containing 9 mu g of haemagglutinin (HA) per strain (it = 588) or a conventional 0.5 ml intramuscular vaccine (15 mu g of HA/strain: n = 390). Intradermal,11 TIV induced non-inferior humoral immune responses against all three strains and superior responses against both A strains (H1N1, H3N2) compared with the control. Both vaccines were well tolerated. (C) 2008 Elsevier Ltd. All rights reserved.
- Keywords
- DENDRITIC CELLS, HEPATITIS-B, RABIES VACCINATION, Haemagglutination inhibition, ANTIBODY-RESPONSES, Immune response, Microinjection, Influenza vaccine, Intradermal, IMMUNIZATION, BELIEFS, SYSTEM
Downloads
-
(...).pdf
- full text
- |
- UGent only
- |
- |
- 588.33 KB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-597785
- MLA
- Leroux-Roels, Isabel, et al. “Seasonal Influenza Vaccine Delivered by Intradermal Microinjection: A Randomised Controlled Safety and Immunogenicity Trial in Adults.” VACCINE, vol. 26, no. 51, ELSEVIER SCI LTD, 2008, pp. 6614–19, doi:10.1016/j.vaccine.2008.09.078.
- APA
- Leroux-Roels, I., Vets, E., Freese, R., Seiberling, M., Weber, F., Salamand, C., & Leroux-Roels, G. (2008). Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults. VACCINE, 26(51), 6614–6619. https://doi.org/10.1016/j.vaccine.2008.09.078
- Chicago author-date
- Leroux-Roels, Isabel, Eva Vets, Ralf Freese, Michael Seiberling, Francoise Weber, Camille Salamand, and Geert Leroux-Roels. 2008. “Seasonal Influenza Vaccine Delivered by Intradermal Microinjection: A Randomised Controlled Safety and Immunogenicity Trial in Adults.” VACCINE 26 (51): 6614–19. https://doi.org/10.1016/j.vaccine.2008.09.078.
- Chicago author-date (all authors)
- Leroux-Roels, Isabel, Eva Vets, Ralf Freese, Michael Seiberling, Francoise Weber, Camille Salamand, and Geert Leroux-Roels. 2008. “Seasonal Influenza Vaccine Delivered by Intradermal Microinjection: A Randomised Controlled Safety and Immunogenicity Trial in Adults.” VACCINE 26 (51): 6614–6619. doi:10.1016/j.vaccine.2008.09.078.
- Vancouver
- 1.Leroux-Roels I, Vets E, Freese R, Seiberling M, Weber F, Salamand C, et al. Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults. VACCINE. 2008;26(51):6614–9.
- IEEE
- [1]I. Leroux-Roels et al., “Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults,” VACCINE, vol. 26, no. 51, pp. 6614–6619, 2008.
@article{597785, abstract = {{Influenza vaccines remain largely underused. A promising alternative to Current intramuscular vaccines is a trivalent inactivated influenza vaccine (TIV) delivered using a microinjection system to offer a less invasive and possibly more acceptable vaccination. A phase 11, multicentre, randomised open-label study in 978 healthy adults (18-57 years) evaluated the immunogenicity and safety of intradermal TIV. Subjects received a 0.1 ml injection of intradermal TIV, containing 9 mu g of haemagglutinin (HA) per strain (it = 588) or a conventional 0.5 ml intramuscular vaccine (15 mu g of HA/strain: n = 390). Intradermal,11 TIV induced non-inferior humoral immune responses against all three strains and superior responses against both A strains (H1N1, H3N2) compared with the control. Both vaccines were well tolerated. (C) 2008 Elsevier Ltd. All rights reserved.}}, author = {{Leroux-Roels, Isabel and Vets, Eva and Freese, Ralf and Seiberling, Michael and Weber, Francoise and Salamand, Camille and Leroux-Roels, Geert}}, issn = {{0264-410X}}, journal = {{VACCINE}}, keywords = {{DENDRITIC CELLS,HEPATITIS-B,RABIES VACCINATION,Haemagglutination inhibition,ANTIBODY-RESPONSES,Immune response,Microinjection,Influenza vaccine,Intradermal,IMMUNIZATION,BELIEFS,SYSTEM}}, language = {{eng}}, number = {{51}}, pages = {{6614--6619}}, publisher = {{ELSEVIER SCI LTD,}}, title = {{Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults}}, url = {{http://doi.org/10.1016/j.vaccine.2008.09.078}}, volume = {{26}}, year = {{2008}}, }
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: